Royalty Pharma plc (RPRX) financial statements and ratios from SEC XBRL: revenue $2.4B (TTM), net margin 32.4%, revenue growth 11.0% YoY, P/E 41.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $2.38B |
| Revenue (TTM) | $2.4B |
| Net Margin | 32.4% |
| Operating Margin (TTM) | 65.1% |
| Net Debt / EBITDA | 5.3 |
| Revenue Growth (YoY) | 11.0% |
| EPS Growth (YoY) | 21.8% |
| P/E Ratio | 41.3 |
| EV / EBITDA | 26.7 |
| Price / Book | 3.43 |
| Price / Sales | 13.99 |
| Altman Z-Score | 2.70 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
RPRX overview · RPRX earnings · RPRX KPIs · RPRX documents · RPRX ownership · RPRX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.